Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | 20.03M | $62.0M | 15.21% | +11.06M | 2026-06-30 |
| T. Rowe Price Investment Management, Inc. | 18.87M | $58.0M | 14.33% | +7.79M | 2026-06-30 |
| Bain Capital Life Sciences Investors, LLC | 17.24M | $53.0M | 13.09% | +7.56M | 2026-06-30 |
| BlackRock, Inc. | 10.75M | $33.0M | 8.17% | +8.38M | 2026-06-30 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.17M | $28.0M | 6.97% | +345.0K | 2026-06-30 |
| STATE STREET CORP | 7.84M | $24.0M | 5.95% | +7.37M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.23M | $22.0M | 5.49% | +3.20M | 2026-06-30 |
| Cormorant Asset Management, LP | 5.00M | $15.0M | 3.80% | -500.0K | 2026-06-30 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.42M | $13.0M | 3.36% | +3.98M | 2026-06-30 |
| Woodline Partners LP | 4.20M | $13.0M | 3.19% | +2.95M | 2026-06-30 |
